drugset
drugset / Trial / NCT06963177

A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

NCT06963177 ↗

Phase 2 Recruiting 200 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate the safety and efficacy of GenSci048 for moderate to severe endometriosis-associated pain treatment.

Timeline

Start
2025-05-26
Primary completion
2028-05-15
Completion
2030-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Genakumab Monoclonal antibody — Subcutaneous

Indications

endometriosis